DLYE5953A / Roche - LARVOL DELTA

ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload (AACR 2025) - "The antibody binding, internalization and spheroid penetration were all superior to the hu9B12.v12 clinical benchmark antibody and ZW327 exhibited pronounced cytotoxicity when compared to DLYE5953A clinical benchmark ADC. A single administration of ZW327 resulted in tumor regression across xenograft models and demonstrated a favorable PK profile. Overall, these results support the potential of ZW327 as a novel therapeutic agent against Ly6E-bearing cancers."

Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • Triple Negative Breast Cancer • LY6E